PART I Company Overview Unless otherwise provided in this Annual Report, references to the Company, we, us, and our refer to Puma Biotechnology, Inc. and our wholly owned subsidiary. We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment ofcertain HER2-positivebreast cancers.Additionally, we have in-licensed...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001437749-26-005891 | EDGAR | 108K words |
| 2025-02-27 | 2024-12-31 | 0001437749-25-005496 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001437749-24-006121 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001437749-23-005233 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001437749-22-005164 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009840 | EDGAR | — |
| 2020-02-28 | 2019-12-31 | 0001564590-20-007591 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001564590-19-005830 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001564590-18-005152 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001564590-17-003090 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001437749-25-033633 | EDGAR | 36K words |
| 2025-08-07 | 2025-06-30 | 0001437749-25-025470 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001437749-25-015533 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001437749-24-033955 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001437749-24-024309 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001437749-24-014395 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001437749-23-030028 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001437749-23-021972 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001437749-23-012589 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001437749-22-025787 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001437749-22-018920 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001437749-22-011142 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001437749-26-005869 | EDGAR | 4K words |
| 2025-11-06 | 0001437749-25-033604 | EDGAR | — |
| 2025-08-07 | 0001437749-25-025463 | EDGAR | — |
| 2025-06-24 | 0001437749-25-021153 | EDGAR | — |
| 2025-06-13 | 0001437749-25-020321 | EDGAR | — |
| 2025-05-09 | 0001437749-25-015648 | EDGAR | — |
| 2025-05-08 | 0001437749-25-015514 | EDGAR | — |
| 2025-02-27 | 0001437749-25-005477 | EDGAR | — |
| 2024-11-07 | 0001437749-24-033929 | EDGAR | — |
| 2024-09-16 | 0001437749-24-029206 | EDGAR | — |
277 total filings indexed. 245 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001401667 |
| Ticker | PBYI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pumabiotechnology.com |
| Listed | 2012-03-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report